What is Allogene Therapeutics's G&A?

Allogene Therapeutics (ALLO) reported G&A of $14.09M in Q1 2026.

How has Allogene Therapeutics's G&A changed year-over-year?

Allogene Therapeutics's G&A decreased by 6.0% year-over-year, from $14.99M to $14.09M.

What is the long-term trend for Allogene Therapeutics's G&A?

Over 4 years (2021 to 2025), Allogene Therapeutics's G&A has grown at a -6.4% compound annual growth rate (CAGR), from $74.11M to $56.78M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Allogene Therapeutics ALLO G&A

G&A at other companies

CRISPR TherapeuticsCRSP

$17.18M-11.0%

Sana BiotechnologySANA

$11.46M-0.2%

CytomX TherapeuticsCTMX

$10.69M+13.4%

Immix Biopharma, Inc.IMMX

$4.82M+78.1%

Vor BiopharmaVOR

$17.57M+167%

Kyverna Therapeutics, Inc.KYTX

$11.29M+13.2%

Other financials

Income statement

See full

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

See full

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

See full

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

See full

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Allogene Therapeutics's G&A?: Allogene Therapeutics (ALLO) reported G&A of $14.09M in Q1 2026.
How has Allogene Therapeutics's G&A changed year-over-year?: Allogene Therapeutics's G&A decreased by 6.0% year-over-year, from $14.99M to $14.09M.
What is the long-term trend for Allogene Therapeutics's G&A?: Over 4 years (2021 to 2025), Allogene Therapeutics's G&A has grown at a -6.4% compound annual growth rate (CAGR), from $74.11M to $56.78M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.